Analysts Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $337.91

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the twenty-four brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and twenty have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $340.00.

Several analysts recently issued reports on the company. Wall Street Zen lowered Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, June 14th. Scotiabank raised their target price on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a research note on Monday, March 31st. William Blair reaffirmed an "outperform" rating on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Canaccord Genuity Group lifted their price target on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. Finally, Citigroup increased their price objective on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a research report on Friday, March 21st.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 19,297 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the completion of the transaction, the chief executive officer directly owned 48,948 shares in the company, valued at approximately $14,978,088. This represents a 28.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.20% of the company's stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. AG2R LA Mondiale Gestion D Actifs bought a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $1,573,000. Swedbank AB grew its position in shares of Alnylam Pharmaceuticals by 8.0% during the 1st quarter. Swedbank AB now owns 59,993 shares of the biopharmaceutical company's stock valued at $16,199,000 after purchasing an additional 4,461 shares in the last quarter. Strs Ohio bought a new position in shares of Alnylam Pharmaceuticals in the 1st quarter worth $7,781,000. Geneos Wealth Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 372.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company's stock worth $60,000 after purchasing an additional 175 shares in the last quarter. Finally, IFM Investors Pty Ltd raised its stake in shares of Alnylam Pharmaceuticals by 0.6% during the first quarter. IFM Investors Pty Ltd now owns 23,850 shares of the biopharmaceutical company's stock worth $6,440,000 after acquiring an additional 150 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY traded up $6.23 during mid-day trading on Friday, hitting $328.29. The company's stock had a trading volume of 581,065 shares, compared to its average volume of 857,541. Alnylam Pharmaceuticals has a fifty-two week low of $205.87 and a fifty-two week high of $339.59. The stock has a market capitalization of $42.81 billion, a price-to-earnings ratio of -156.62 and a beta of 0.23. The firm has a 50-day moving average price of $289.81 and a 200 day moving average price of $264.42. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The firm had revenue of $594.19 million for the quarter, compared to analysts' expectations of $584.32 million. During the same period in the prior year, the company posted ($0.16) earnings per share. Alnylam Pharmaceuticals's quarterly revenue was up 20.2% compared to the same quarter last year. On average, research analysts predict that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.